CALI Trial Information
I cannot provide details about a "CALI trial" (Clopidogrel and Aspirin in Ischemic Events) because no such trial exists in the medical literature or evidence provided. You may be confusing this with other major antiplatelet trials that have similar acronyms or study designs.
Major Clopidogrel Trials You May Be Referring To:
CAPRIE Trial (Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events)
- Enrolled 19,185 patients with atherosclerotic vascular disease (recent stroke, recent MI, or symptomatic peripheral arterial disease) 1, 2
- Compared clopidogrel 75 mg daily versus aspirin 325 mg daily for 1-3 years 1, 2
- Primary outcome: Composite of ischemic stroke, MI, or vascular death occurred in 5.32% with clopidogrel versus 5.83% with aspirin 2
- Result: Clopidogrel reduced relative risk by 8.7% (95% CI 0.3-16.5%, p=0.043) compared to aspirin 1, 2
- Safety: Similar overall safety profile with lower gastrointestinal bleeding rates with clopidogrel (1.99% vs 2.66%, p<0.002) 3
CURE Trial (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events)
- Enrolled 12,562 patients with acute coronary syndrome without ST-elevation presenting within 24 hours 1, 4
- Compared clopidogrel (300 mg loading dose, then 75 mg daily) plus aspirin versus placebo plus aspirin for up to 12 months 1, 4
- Primary outcome: CV death, MI, or stroke occurred in 9.3% with clopidogrel versus 11.4% with placebo 1, 4
- Result: 20% relative risk reduction (95% CI 10-28%, p<0.001) with clopidogrel 1, 4
- Bleeding: Major bleeding increased from 2.7% to 3.7% (p<0.001) 1
CHARISMA Trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance)
- Designed to evaluate clopidogrel plus aspirin versus aspirin alone in patients with established vascular disease or multiple risk factors 1, 5
- This trial showed no significant benefit in stable high-risk patients and observed only one-third to one-half of the expected benefit 1
POINT Trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke)
- Enrolled 4,881 patients with minor ischemic stroke or high-risk TIA 6
- Compared clopidogrel (600 mg loading, then 75 mg daily) plus aspirin versus aspirin alone for 90 days 6
- Result: Major ischemic events reduced from 6.5% to 5.0% (HR 0.75,95% CI 0.59-0.95, p=0.02) 6
- Bleeding: Major hemorrhage increased from 0.4% to 0.9% (HR 2.32,95% CI 1.10-4.87, p=0.02) 6
If you are looking for information about a specific trial, please verify the correct trial name or acronym.